Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Good
|
New words:
Amberglen, arbitration, avidity, binding, Blvd, buildout, circulating, CMV, Connecticut, correlate, dendritic, genotype, immunophenotype, immunosuppressive, inhibitor, intracellular, inversely, lab, MDSC, MOA, modest, muscle, NW, preferential, Proportion, purport, rash, reader, rent, routing, saturate, Score, soluble, supplier, text, TX, vascular, VEGF
Removed:
advancement, amortize, cancelled, central, communicating, contingency, continually, contracting, deployed, direction, disappeared, driven, expectancy, gastric, geography, half, hepatic, Hubei, incurable, infected, initially, investigator, jointly, led, manager, microenvironment, muscular, partnered, pertuzumab, predicated, Province, RECIST, refractory, reinstituting, relapsed, remotely, screen, selection, shelter, SPA, suspending, temporarily, threat, trastuzumab, treating, unmeasurable, variable
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view